MannKind is facing a cash shortfall unless it can settle with debt holders by August.
When a biotech CEO diverts from safe, bland corporate tweets to engage in some clever competitive trolling, I stand and applaud.
Biogen has added $25 billion in market value since the December -- a sign investors are willing to believe BIIB037 might succeed where several other similar Alzheimer's drugs have failed.
The cross-trial comparison between CTI BioPharma's pacritinib and Incyte's Jakafi looks worse than expected.
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Neuralstem is providing an overly optimistic picture about its surgical stem-cell therapy for amyotrophic lateral sclerosis (ALS), the degenerative and fatal nerve disease.
Biotech companies are experiencing an unprecedented run of scientific successes, but biotech stock valuations have never been more expensive.
Acadia admits that it can't seek approval for its Parkinson's psychosis drug this quarter, as promised. The company's CEO also resigned.
Skin cancer patients in Britain can be treated with Merck's Keytruda before the cancer immunotherapy drug is approved there under a new early access plan announced Wednesday.
It won't be easy to compare the phase II trail results from Genfit and Intercept's competing NASH drugs, but understanding the differences in their respective clinical trials should help.